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Several unmet scientific needs that account for the partial
failure of MTCT prevention efforts in resource-con-
strained settings, particularly in Africa. Single-dose and
short-course antiretroviral (ARV) regimens are only par-
tially effective and have failed to achieve wide coverage
despite their apparent simplicity. More potent ARV com-
binations are restricted to pregnant women who need
treatment for themselves but are also infrequently used.
Furthermore, postnatal transmission via breastfeeding is a
serious additional threat. Modifications of infant feeding
practices aim to reduce breast-milk HIV transmission:
replacement feeding is neither affordable nor safe for the
majority of African women, and early breastfeeding cessa-
tion (e.g. prior to 6 months of life) requires substantial
care and nutritional counselling to be practised safely.
We argue that the recent roll out of highly active ARV treat-
ment (HAART) has changed the paradigm of prevention
of MTCT. To date, postnatal ARV interventions that have
been evaluated target either maternal ARV treatment to
selected breastfeeding women, with good efficacy, or sin-
gle-drug post-exposure prophylaxis for short periods of
time to their neonates, with a partial efficacy and at the
expense of acquisition of drug-related viral resistance. We
hypothesize that a viable solution to eliminate paediatric
AIDS lies in the universal provision of HAART to all HIV-
infected women through pregnancy, delivery, and cover-
ing the entire breastfeeding period.
We suggest the active promotion of the universal maternal
HAART approach as a way towards elimination of MTCT
in resource-limited settings. We argue that HAART should
be made available to all HIV-infected pregnant women in
resource-limited settings, irrespective of their CD4 count
or clinical stage, and even to those who present late in
pregnancy. This universal ARV-based strategy will be
accompanied by proper pharmacovigilance systems. It
should consider the breastfeeding cessation around six
months of age, which implies the need for a proper and
systematic nutritional support. Continuing investigations
will compare the safety, acceptability, feasibility and effi-
ciency of various maternal HAART regimens for prevent-
ing MTCT throughout the entire exposure period in order
to rank them according to the best risk-benefit balance.
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